Instead, clinicians are entering an era where diabetes care and hepatology increasingly overlap, especially as metabolic dysfunction-associated steatotic liver disease, or MASLD, becomes Read More GLP1s and Liver Disease: Rethinking MASLD Care Beyond Obesity and A1C Jan 26, 2026 Articles, Diabetes, Featured, Obesity, Therapies, Type 2 Diabetes, Type 2 Diabetes 2,674 views Nonalcoholic steatohepatitis (NASH) and metabolic dysfunctionassociated steatotic liver disease (MASLD) are rapidly becoming leading causes of chronic liver disease worldwide
Cows: 4 weeks before joining and calving
Gao et al., 2009
Air travel Airplane cargo holds are not temperature controlled in the same way as the cabin
He said pills from Eli Lilly and Pfizer are non-peptide GLP-1s, which are absorbed more easily and don't require dietary restrictions